MRG 003
Phase 2Small molecule
MRG 003 is one of 17 small molecule programs targeting Salivary Gland Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Salivary Gland Cancer
#DrugCompanyPhaseTrials
1Zoladex
TTerSera Therapeutics LLC
Approved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Keytruda
Merck & Co.Phase 2
Navmi
SSummit Therapeutics
Phase 2
Paraplatin
AAvyxa
Phase 2
Alimta
EEagle Pharmaceuticals, Inc.
Phase 2
Pucotenlimab
SSun Yat-sen University
Phase 2
Xpovio
KKaryopharm Therapeutics Inc
Preclinical
Casodex
IIstituto Clinico Humanitas
Preclinical
Leuprorelin
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MRG 003. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- JJi Dongmei